title: What Your Doctor May Not Tell You About(TM): Breast Cancer: How Hormone Balance Can Help Save Your Life
author: John R. Lee
description: An informative and absorbing read for both medical practitioners and their patients, <i>What Your Doctor May Not Tell You About Breast Cancer</i> takes aim at "the breast cancer industry" with a barrage of thought-provoking ammunition.
zlib_text: TAMOXIFEN
  CAS No. 10540-29-1 
  First Listed in the Ninth Report on Carcinogens 
  CARCINOGENICITY
  Tamoxifen is known to be a human carcinogen based on sufficient evidence of
  carcinogenicity in humans that indicates a causal relationship between exposure to tamoxifen and
  cancers of the uterine endometrium. However, there is also conclusive evidence that tamoxifen
  therapy reduces the risk of contralateral breast cancer in women with a previous diagnosis of 
  breast cancer, and may prevent or delay the occurrence of breast cancer in women at increased
  risk for this disease (IARC 1996). The potential effect of tamoxifen in increasing the risk of 
  endometrial cancer has been reported in one adequate cohort study, four adequate case-control
  studies, and 14 randomized clinical trials. 
  The cohort study (Curtis et al. 1996) examined the effect of tamoxifen on risk of 
  endometrial cancer in 87,323 women with breast cancer reported to the Surveillance,
  Epidemiology, and End Results (SEER) program in